文献速递乳腺癌放疗放疗物理与技术

加速部分乳腺照射中三维适形外照射放疗与单入口多腔腔内近距离放疗的毒性和美容效果前瞻性比较

Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation With Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy.
PubMed 文献 · Pract Radiat Oncol · 2018-08-17

中位随访41个月,近距离放疗的1级纤维化和血清肿发生率高于三维适形放疗,但1级水肿和2-3级疼痛发生率低于三维适形放疗;两组5年同侧乳腺复发率相当。

要点

  • 近距离放疗的1级纤维化(66.3% vs 44.8%)和血清肿(50.4% vs 3.4%)发生率高于三维适形放疗。
  • 三维适形放疗的1级水肿(17.2% vs 5.6%)和2-3级疼痛(17.2% vs 5.2%)发生率高于近距离放疗。
  • 近距离放疗与更差的美容效果显著相关(混合模型分析P=0.003),5年同侧乳腺复发率两组相当(4.3% vs 4.2%,P=0.95)。

核心结论

  • 近距离放疗加速部分乳腺照射的1级纤维化和血清肿发生率高于三维适形放疗,但1级水肿和2-3级疼痛发生率低于三维适形放疗。
  • 近距离放疗的放射肿瘤科医生报告的美容效果一般或差的比例更高。
  • 研究识别了预测近距离放疗后不良美容效果风险降低的剂量学参数。
  • 近距离放疗与三维适形放疗的同侧乳腺复发率相当。

研究设计与样本

  • 前瞻性研究,2008年12月至2014年8月入组281例pTis、pT1N0或pT2N0(≤3.0 cm)且接受乳腺区段切除术的乳腺癌患者。
  • 加速部分乳腺照射采用三维适形放疗(n=29)或近距离放疗导管(SAVI n=176、Contura n=56、MammoSite n=20)。
  • 按方案规定间隔评估,由放射肿瘤科医生采用标准化模板对美容效果、毒性和复发状态进行评分。

主要发现

  • 中位随访时间41个月。
  • 1级血清肿在近距离放疗组为50.4%、三维适形放疗组为3.4%(P<.0001);1级纤维化在近距离放疗组为66.3%、三维适形放疗组为44.8%(P=.02)。
  • 1级水肿在三维适形放疗组为17.2%、近距离放疗组为5.6%(P=.04);2-3级疼痛在三维适形放疗组为17.2%、近距离放疗组为5.2%(P=.03)。
  • 放射肿瘤科医生报告的5年美容效果一般或差的比例:三维适形放疗组9%、近距离放疗组24%(P=.13);混合模型分析显示近距离放疗与更差的美容效果显著相关(P=.003)。
  • 近距离放疗后不良美容效果风险降低的显著预测因素包括D0.1cc(皮肤)≤102%、最小皮肤距离>5.1 mm、剂量均匀性指数>0.54、非适形体积≤0.89 cc;5年同侧乳腺复发率近距离放疗组4.3%、三维适形放疗组4.2%(P=.95)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to prospectively characterize toxicity and cosmesis after accelerated partial breast irradiation (APBI) with 3-dimensional conformal radiation therapy (CRT) or single-entry, multilumen, intracavitary brachytherapy. METHODS AND MATERIALS: A total of 281 patients with pTis, pT1N0, or pT2N0 (≤3.0 cm) breast cancer treated with segmental mastectomy were prospectively enrolled from December 2008 through August 2014. APBI was delivered using 3-dimensional CRT (n = 29) or with SAVI (n = 176), Contura (n = 56), or MammoSite (n = 20) brachytherapy catheters. Patients were evaluated at protocol-specified intervals, at which time the radiation oncologist scored cosmetic outcome, toxicities, and recurrence status using a standardized template. RESULTS: The median follow-up time is 41 months. Grade 1 seroma and fibrosis were more common with brachytherapy than with 3-dimensional CRT (50.4% vs 3.4% for seroma; P < .0001 and 66.3% vs 44.8% for fibrosis; P = .02), but grade 1 edema was more common with 3-dimensional CRT than with brachytherapy (17.2% vs 5.6%; P = .04). Grade 2 to 3 pain was more common with 3-dimensional CRT (17.2% vs 5.2%; P = .03). Actuarial 5-year rates of fair or poor radiation oncologist-reported cosmetic outcome were 9% for 3-dimensional CRT and 24% for brachytherapy (P = .13). Brachytherapy was significantly associated with inferior cosmesis on mixed model analysis (P = .003). Significant predictors of reduced risk of adverse cosmetic outcome after brachytherapy were D0.1cc (skin) ≤102%, minimum skin distance >5.1 mm, dose homogeneity index >0.54, and volume of nonconformance ≤0.89 cc. The 5-year ipsilateral breast recurrence was 4.3% for brachytherapy and 4.2% for 3-dimensional CRT APBI patients (P = .95). CONCLUSIONS: Brachytherapy APBI is associated with higher rates of grade 1 fibrosis and seroma than 3-dimensional CRT but lower rates of grade 1 edema and grade 2 to 3 pain than 3-dimensional CRT. Rates of radiation oncologist-reported fair or poor cosmetic outcomes are higher with brachytherapy. We identified dosimetric parameters that predict reduced risk of adverse cosmetic outcome after brachytherapy-based APBI. Ipsilateral breast recurrence was equivalent for brachytherapy and 3-dimensional CRT.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Stecklein SR, Shaitelman SF, Babiera GV, et al. Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation With Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy. Pract Radiat Oncol. 2018. PMID: 30125673. doi:10.1016/j.prro.2018.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。